Department of Medicine, University of Colorado Denver, Aurora, Colorado 80045, USA.
Nat Rev Drug Discov. 2012 Aug;11(8):633-52. doi: 10.1038/nrd3800.
Interleukin-1 (IL-1) is a highly active pro-inflammatory cytokine that lowers pain thresholds and damages tissues. Monotherapy blocking IL-1 activity in autoinflammatory syndromes results in a rapid and sustained reduction in disease severity, including reversal of inflammation-mediated loss of sight, hearing and organ function. This approach can therefore be effective in treating common conditions such as post-infarction heart failure, and trials targeting a broad spectrum of new indications are underway. So far, three IL-1-targeted agents have been approved: the IL-1 receptor antagonist anakinra, the soluble decoy receptor rilonacept and the neutralizing monoclonal anti-IL-1β antibody canakinumab. In addition, a monoclonal antibody directed against the IL-1 receptor and a neutralizing anti-IL-1α antibody are in clinical trials.
白细胞介素-1（IL-1）是一种高度活跃的促炎细胞因子，可降低痛阈并损害组织。在自身炎症性疾病中单药阻断 IL-1 活性可迅速且持续地减轻疾病严重程度，包括逆转炎症介导的视力、听力和器官功能丧失。因此，这种方法可有效治疗常见疾病，如心肌梗死后心力衰竭，针对广泛新适应证的试验正在进行中。迄今为止，已有三种靶向 IL-1 的药物获得批准：白细胞介素-1 受体拮抗剂阿那白滞素、可溶性诱饵受体瑞那司特和中和单克隆抗白细胞介素-1β 抗体卡那单抗。此外，一种针对白细胞介素-1 受体的单克隆抗体和一种中和抗白细胞介素-1α 抗体正在临床试验中。
